JAK1 and peeling skin syndrome: Notable, promising research by Renaudineau and colleagues suggests that JAK1/2 inhibitors, AG490 and ruxolitinib, may reverse specific pathways implicated in pSS pathogenesis (McCoy et al., 2022).